---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-001748"
form_type: "8-K"
ticker: "VACH"
cik: "0002006815"
company_name: "Voyager Acquisition Corp./Cayman Islands"
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:13:46.745557+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VERAXA shareholders approve merger with Voyager SPAC; CHF 223,400 capital increase

## Summary
- Shareholders approved absorption merger of VERAXA into Veraxa Biotech Holding AG; combined entity to rename to Veraxa Biotech AG.
- Approved ordinary capital increase of CHF 223,400 for shares to be issued to Voyager shareholders.
- Christoph Antz remains CEO; closing subject to Voyager shareholder vote; Nasdaq ticker expected to be VRXA.
- Business combination originally announced April 22, 2025; proxy statement/prospectus filed Feb 19, 2026.

## SEC filing metadata
- accession: 0001829126-26-001748
- form_type: 8-K
- ticker: VACH
- cik: 0002006815
- company_name: Voyager Acquisition Corp./Cayman Islands
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006815/000182912626001748/0001829126-26-001748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006815/000182912626001748/voyageracq_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-001748
- JSON: https://secwatch.observer/filing/0001829126-26-001748.json
- Plain text: https://secwatch.observer/filing/0001829126-26-001748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.